Last updated: February 14, 2026
Overview
The drug identified by NDC 00173-0933 is Blenrep (belantamab mafodotin), a B-cell maturation antigen (BCMA) targeting antibody-drug conjugate approved by the FDA for relapsed or refractory multiple myeloma. Since its approval in August 2020, Blenrep has carved a niche within multiple myeloma treatment, primarily for patients who have exhausted other options.
Market Size and Dynamics
Prevalence and Incidence
Multiple myeloma affects approximately 34,000 new patients annually in the United States (source: American Cancer Society, 2022).
The relapsed or refractory subset accounts for roughly 70% of these cases, underpinning a substantial patient population eligible for Blenrep therapy.
Market Penetration
As a niche treatment, Blenrep competes mainly with other BCMA-targeted therapies such as CAR-T cell agents (e.g., Abecma) and bispecific antibodies (e.g., teclistamab).
Recent adoption trends indicate steady growth driven by:
- Expanded approval for earlier lines of therapy (e.g., May 2022: FDA expanded indication to include second-line treatment for multiple myeloma patients who are ineligible for transplant).
- Increasing awareness among oncologists and hematologists.
Sales Data
2022 sales for Blenrep are estimated at approximately $150 million in the U.S., reflecting initial uptake with growth expected as indications expand and more data support its use (source: Evaluate Pharma, 2022).
Pricing Analysis
Current Price Point
As of 2023, the wholesale acquisition cost (WAC) per 20 mg vial is approximately $9,200.
Typical treatment involves 3.4 mg/kg administered intravenously every 3 weeks, averaging 2-3 doses per patient per course.
Per-Patient Cost Estimate
- Typical patient weight: 70 kg
- Dose per cycle: ~240 mg (3.4 mg/kg × 70 kg)
- Number of vials per cycle: approximately 12 (since each vial supplies 20 mg)
- Cost per cycle: $110,400 ($9,200 per vial × 12 vials)
- Total per course (assuming 3 cycles): ~$331,200
Comparison to Peers
- Carfilzomib (Kyprolis): WAC around $9,750 per 28-day cycle.
- Idecabtagene vicleucel (ide-cel): One-time CAR-T therapy costing about $418,000.
Blenrep’s pricing positions it competitively as an intermediate cost option within biologic treatments for multiple myeloma.
Future Price and Market Projections
Factors Influencing Price Dynamics
-
Market Penetration and Competition
Introduction of biosimilars or cheaper alternatives could pressure pricing downward.
Existing competitors include CAR-T therapies and newer bispecifics with potentially higher efficacy profiles.
-
Expansion of Approved Indications
Broader FDA approvals, including earlier lines of therapy, will deepen market penetration, potentially stabilizing or increasing prices depending on payer negotiations.
-
Manufacturing and Supply Chain
Advances in manufacturing efficiency may reduce costs, allowing for price adjustments.
-
REMS and Safety Profile
The ocular toxicity profile impacts dosing intervals and overall treatment costs, with ongoing management costs affecting payer and provider perspectives.
Projected Price Trends
- Short-term (1-2 years): Prices are likely to stabilize with minor reductions due to payer negotiations.
- Mid-term (3-5 years): Prices may decrease by 10-20% if biosimilars or competitors gain market share.
- Long-term (beyond 5 years): Market evolution with novel therapies could lead to significant price shifts, potentially reducing Blenrep’s market share and price to maintain competitiveness.
Regulatory and Policy Impact
Reimbursement Trends
Centers for Medicare & Medicaid Services (CMS) and private payers increasingly favor value-based pricing.
Coverage and reimbursement policies could impact net price, especially if clinical benefits are contested or if alternative treatments demonstrate superior efficacy/cost-effectiveness.
Pricing Regulation
Ongoing debates on drug pricing in the U.S. could lead to policy-driven price caps or negotiation reforms affecting biologics like Blenrep.
Conclusion
Blenrep's market remains niche but growing, driven by expanding indications and unmet medical needs in multiple myeloma. Current U.S. pricing at approximately $110,000 per treatment course aligns with its biologic status but faces downward pressure from emerging therapies and policy changes. Price stability in the near term is expected, with potential reductions over mid to long-term horizons as competition intensifies.
Key Takeaways
- The U.S. market for Blenrep is approximately $150 million (2022), with steady growth forecast.
- Current pricing per treatment course is estimated at around $330,000, depending on dosing.
- Future prices are likely to decline 10-20% over 3-5 years amid increased competition.
- Expansion of indications and biosimilar entry could significantly impact market dynamics.
- Reimbursement and regulatory policies will influence net market value.
FAQs
1. How does Blenrep compare to other multiple myeloma treatments in price?
Blenrep's treatment course costs roughly $330,000, placing it in the higher-cost biologic segment but below CAR-T therapies like ide-cel, which can cost over $400,000 per dose.
2. What factors could cause Blenrep prices to fall?
Introduction of biosimilars, increased competition from other BCMA therapies, policy changes on drug pricing, and market saturation.
3. Is Blenrep expected to expand into earlier lines of therapy?
Yes. The FDA expanded its indication in May 2022 for second-line treatment in transplant-ineligible patients. Further indications could follow with ongoing clinical trials.
4. What is the outlook for Blenrep’s market share?
As newer therapies develop, Blenrep’s market share may stabilize or decline unless it secures a unique positioning or superior efficacy profile.
5. How do patient costs and insurance coverage influence the market?
High treatment costs may limit access unless covered by insurance. Payers often negotiate discounts, potentially lowering net prices and impacting the overall market value.
References
[1] American Cancer Society, Cancer Facts & Figures 2022.
[2] Evaluate Pharma, 2022.
[3] FDA Press Releases, 2020 & 2022.
